These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29683789)

  • 21. Cancer immunotherapy: weak beats strong.
    Deppert W; Bruns M
    Aging (Albany NY); 2016 Nov; 8(11):2607-2608. PubMed ID: 27920406
    [No Abstract]   [Full Text] [Related]  

  • 22. Commentary on Pharmacometrics for Immunotherapy.
    Garrido MJ; Berraondo P; Trocóniz IF
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):8-10. PubMed ID: 27997736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis.
    Banerjee D; Monaghan S; Zhao R; Walsh T; Palmisciano A; Phillips GS; Opal S; Levy MM
    Crit Care; 2018 Jun; 22(1):146. PubMed ID: 29875013
    [No Abstract]   [Full Text] [Related]  

  • 24. Monitoring immunotherapy outcomes with circulating tumor DNA.
    Goldberg SB; Patel AA
    Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?
    Labrador-Horrillo M; Selva-O'Callaghan A
    J Rheumatol; 2018 Jun; 45(6):731-732. PubMed ID: 29858454
    [No Abstract]   [Full Text] [Related]  

  • 26. [Not Available].
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):262b. PubMed ID: 29176293
    [No Abstract]   [Full Text] [Related]  

  • 27. A potential biomarker for anti-PD-1 immunotherapy.
    Goswami S; Basu S; Sharma P
    Nat Med; 2018 Feb; 24(2):123-124. PubMed ID: 29414936
    [No Abstract]   [Full Text] [Related]  

  • 28. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
    Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
    Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
    Li Y; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
    Sanmamed MF; Chen L
    Cell; 2018 Oct; 175(2):313-326. PubMed ID: 30290139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy.
    Reading JL; Quezada SA
    Immunity; 2016 Dec; 45(6):1181-1183. PubMed ID: 28002724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making cancer immunotherapy a surer bet.
    Eisenstein M
    Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
    [No Abstract]   [Full Text] [Related]  

  • 33. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
    Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V
    Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843
    [No Abstract]   [Full Text] [Related]  

  • 35. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 36. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
    Ni JM; Ni AP
    Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Emerging Immunotargets in Genitourinary Tumors.
    Montironi R; Santoni M; Massari F; Lopez-Beltran A; Cheng L; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):748-9. PubMed ID: 27086839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.